Oncotelic Therapeutics, Inc. (OTLC)

Every figure this model derived for OTLC, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2015-12-31
cash 2,712,000 CashAndCashEquivalentsAtCarryingValue 2025-09-30
current assets 1,460,742 AssetsCurrent 2026-06-30
current liabilities 17,906,958 LiabilitiesCurrent 2026-06-30
equity 264,561,051 StockholdersEquity 2026-06-30
revenue 70,000 Revenues 2023-12-31
sbc 0 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up OTLC on one particular measure came for.

RatioValue
current ratio0.08
current ratio reported0.08
growth cv1.59
revenue growth-95.98
revenue growth per share-95.98
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about OTLC's figures. Written by the derivation as it ran, not added afterwards.